| 115.07 0.02 (0.02%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 134.47 | 1-year : | 157.06 |
| Resists | First : | 115.12 | Second : | 134.47 |
| Pivot price | 115  |
|||
| Supports | First : | 114.72 | Second : | 114.47 |
| MAs | MA(5) : | 115.06 |
MA(20) : | 114.94 |
| MA(100) : | 90.12 |
MA(250) : | 80.06 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 83.4 |
D(3) : | 83.2 |
| RSI | RSI(14): 79.8 | |||
| 52-week | High : | 115.12 | Low : | 47.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACLX ] has closed below upper band by 29.5%. Bollinger Bands are 98.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 115.18 - 115.74 | 115.74 - 116.22 |
| Low: | 113.7 - 114.36 | 114.36 - 114.93 |
| Close: | 114.1 - 115.1 | 115.1 - 115.98 |
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Thu, 11 Jun 2026
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Tue, 28 Apr 2026
Arcellx (ACLX) director-linked fund exits as Gilead buyout closes - Stock Titan
Tue, 28 Apr 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
Mon, 27 Apr 2026
Are Medical Stocks Lagging Arcellx (ACLX) This Year? - Yahoo Finance
Wed, 25 Mar 2026
Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisition - Pharmaceutical Technology
Tue, 10 Mar 2026
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 4.296e+007 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 4,700 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.464e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 850.2 % |
| Return on Equity (ttm) | -24.1 % |
| Qtrly Rev. Growth | 2.229e+007 % |
| Gross Profit (p.s.) | -356.8 |
| Sales Per Share | -213.68 |
| EBITDA (p.s.) | -5.4128e+008 |
| Qtrly Earnings Growth | -4.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -210 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.54 |
| Price to Cash Flow | 4.13 |
| Dividend | 0 |
| Forward Dividend | 1.8e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|